In a trio of recent Pennsylvania Superior Court decisions involving the diet drug Redux, plaintiffs' lawyers may have gained a new cause of action against pharmaceutical manufacturers, but not before the reaffirmance of the learned intermediary defense and the rejection of a plaintiff's unique challenge to that defense.

Please see full article below for more information.